Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Pasquale PaglianoAnna Maria SperaCarmine SellittoGiuliana ScarpatiVeronica FollieroOrnella PiazzaGianluigi FranciValeria ContiTiziana AscionePublished in: Expert opinion on drug discovery (2023)
Nirmatrelvir/ritonavir has a good tolerability profile. Its administration during the early stages of mild-to-moderate COVID-19 holds potential benefits, as it can help prevent the onset of an aberrant immune response that could lead to pulmonary and extra-pulmonary complications. However, its drug - drug interactions can be a factor limiting its use, at least in populations on some chronic therapies, along with the risk of infection relapse after treatment.
Keyphrases
- sars cov
- immune response
- coronavirus disease
- pulmonary hypertension
- respiratory syndrome coronavirus
- antiretroviral therapy
- small molecule
- copy number
- dendritic cells
- stem cells
- toll like receptor
- cell therapy
- dna methylation
- double blind
- inflammatory response
- clinical trial
- gene expression
- combination therapy
- genome wide
- genetic diversity